v3.26.3
Alliance and Collaboration - Schedule of Company’s Alliance and Collaboration Agreements (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Orion Corporation | Balance Sheet Location: us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Deferred income $ 3,445   $ 3,445   $ 4,811
Orion Corporation | Balance Sheet Location: us-gaap:OtherLiabilitiesNoncurrent          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Deferred income 296   296   814
Orion Corporation | Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Collaborative arrangement license revenue agreement (776) $ (912) (1,883) $ (2,677)  
Orion Corporation | Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Collaborative arrangement license revenue agreement (197) (372) (818) (1,131)  
Zambon Biotech S.A. | Balance Sheet Location: us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Deferred income 641   641   0
Zambon Biotech S.A. | Balance Sheet Location: us-gaap:OtherLiabilitiesNoncurrent          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Deferred income 2,725   2,725   2,530
Zambon Biotech S.A. | Location, Statement of Income, Balance [Axis]: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Collaborative arrangement license revenue agreement 1,488 0 1,488 0  
mAbxience S.L. | Balance Sheet Location: us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Deferred income 0   0   7,500
Pfizer Inc. (formerly Metsera, Inc.)          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Proceeds from financing obligations         6,400
Deferred income from manufacturing services         3,000
Pfizer Inc. (formerly Metsera, Inc.) | Balance Sheet Location: us-gaap:OtherLiabilitiesNoncurrent          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Deferred income 22,415   22,415   9,378
Pfizer Inc. (formerly Metsera, Inc.) | Balance Sheet Location: us-gaap:PrepaidExpenseAndOtherAssetsCurrent          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Deferred income 0   0   $ 321
Pfizer Inc. (formerly Metsera, Inc.) | Location, Statement of Income, Balance [Axis]: us-gaap:OtherOperatingIncomeExpenseNet          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Collaborative arrangement license revenue agreement 0 0 (6,877) 0  
Pfizer Inc. (formerly Metsera, Inc.) | Location, Statement of Income, Balance [Axis]: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Collaborative arrangement license revenue agreement $ 0 $ 245 $ 0 $ 2,218